The CEO of Cronos Group Inc., Mike Gorenstein, testified in the U.S. criminal trial of Andrew Left, founder of the short-selling firm Citron Research, telling the jury he was shocked when the prominent short seller published a report claiming the company was overvalued, causing its stock price to plummet. Gorenstein appeared as the prosecution's first witness on Tuesday in the government's case against Left, who is accused of misleading investors by trading quickly in and out of positions after publishing investment advice.
Gorenstein stated that Left's report, published in August 2018, alleged Cronos misled investors regarding distribution commitments. The CEO argued the company had in fact disclosed its supply agreements, which were not the same as sales guarantees. "I never really understood the report," Gorenstein testified in Los Angeles federal court. "It didn't make any sense." He added that Left never contacted the company to verify any of his allegations.
The trial, expected to last about three weeks, has placed the short-selling industry in the spotlight. Left, one of the sector's most famous figures, is accused of illegally manipulating stock prices for quick profits through incendiary social media posts targeting dozens of companies. He has denied any wrongdoing.
In Tuesday's opening statements, prosecutor Andrew Roach told jurors that Left gained fame and influence through a "pump-and-dump, short-and-distort scheme," earning him $20 million over the years. Defense attorney Adam Fee argued in his opening that Left built a reputation over 25 years as a short seller and trader by publicly sharing his views on companies—something valued by investors who made money following his advice.
Gorenstein testified that Left misrepresented statements Cronos made to investors in 2018. Prosecutors played a video clip of an interview with Left after the report's publication. In it, Left claimed he still held a short position and expected the stock to fall further, while in reality he had already closed most of his position by that time.
During cross-examination, defense attorney Eric Rosen pointed out that Left's 2018 price target for Cronos was $3.50, which is consistent with its current value. Cronos's New York-listed stock plunged 28% on the day the report was published but later recovered, ending the year up 34%. The following year, the stock reached highs above $25. It currently trades around $2.77.
The case is docketed as US v. Left, 24-cr-456, in the U.S. District Court for the Central District of California (Los Angeles).
**The Citron Short Report on Cronos Group: A Timeline**
In late August 2018, at the peak of the Canadian cannabis stock frenzy, the prominent short seller Citron Research suddenly turned its focus to the then-hot cannabis producer Cronos Group. The sharply worded short report not only instantly ignited market sentiment but also became a key catalyst for the later securities fraud charges against Citron founder Andrew Left.
At the time, Cronos Group was a darling of the capital markets. As the first "plant-touching" cannabis company to list on a major U.S. exchange, its stock price had soared over 400% within 2018. However, in a report titled "Cronos: The Dark Side of the Cannabis Space," Andrew Left delivered a harsh dose of reality to the "green rush."
**Core Argument: Questioning Supply Chain Authenticity**
The core logic of Citron's short thesis on Cronos centered on questioning the completeness and authenticity of its disclosures. In 2018, the cannabis industry was in a transition period from illegal to legal, and investors placed great importance on supply agreements producers signed with provincial distributors.
Citron's report argued that Cronos intentionally misled investors by exaggerating the solidity of its sales channels. Left found that while Cronos publicly highlighted multiple "supply commitments" with provincial regulators, its formal regulatory filings deliberately omitted details on the scale and enforceability of these agreements. By comparing disclosures, Citron noted that Cronos's agreements were vague compared to the clearly stated supply tonnage figures from competitors. Left bluntly stated this was not a simple oversight but "fraudulent concealment" meant to sustain a high valuation.
Beyond fundamental concerns, Citron employed its signature tactic: a valuation attack. When the report was published, Cronos's stock was at a historic high, with a market capitalization completely disconnected from its modest revenue. The report issued a devastating price target of $3.50, far below the stock's trading price at the time. This extreme pricing strategy instantly shattered retail investor confidence. Left used social media (such as Twitter at the time) and mainstream financial media to repeatedly promote the message that "Cronos is the most overvalued company in the industry," successfully triggering panic selling. On the day of the report's release, Cronos's stock price plunged 28%, erasing market value instantly.
**Controversial "Short and Distort" Tactics**
As the U.S. Department of Justice's criminal case against Left entered the trial phase, further details emerged. Prosecutors allege Left engaged in illegal "scalping" tactics: after the explosive report caused the stock price to crash, Left did not maintain a "long-term short" position as he claimed but instead quickly covered his position at lower prices to lock in profits.
Testimony from Cronos CEO Mike Gorenstein in court also revealed another facet of the short seller's approach—a refusal to engage. Gorenstein pointed out that Citron never contacted the company to verify any details before publishing its allegations, opting instead for the most disruptive surprise attack. This "shoot first, ask questions later" approach, while lucrative for Citron, also laid the groundwork for future legal challenges.
**The Aftermath**
Citron's short campaign against Cronos was a classic combination of psychological warfare and data analysis. It exploited weaknesses in an emerging industry—opaque regulation and exuberant investor sentiment—and achieved precise gains by magnifying flaws in the company's disclosures. Although years later Cronos's stock price did fall to the level Left predicted, his misleading statements during the trading process have also transformed him from a "market watchdog" into a defendant in a criminal trial. This case is not only a nightmare for Cronos but also represents a significant turning point in the history of global financial regulation.
Comments